greeksoup/ stock research
Stock research / United States / COO · Ophthalmic Goods · Nasdaq

Cooper Companies, Inc. (COO)

Cooper is a global medical device company headquartered in San Ramon, California, selling products in over 130 countries. It runs two business segments, CooperVision in vision care and CooperSurgical in fertility and women's health. The financial year ends on 31 October.

Cooper Companies, Inc.

Cooper is a global medical device company headquartered in San Ramon, California, selling products in over 130 countries. It runs two business segments, CooperVision in vision care and CooperSurgical in fertility and women's health. The financial year ends on 31 October.

CooperVision

The segment develops, makes and markets single-use, two-week and monthly contact lenses, designed for vision problems including astigmatism, presbyopia and myopia across spherical, toric and multifocal lenses, using materials such as silicone hydrogel Aquaform. It also makes myopia management products, including the MiSight 1 day lens developed in-house, and specialty eyecare products such as orthokeratology and scleral lenses. In November 2019 MiSight 1 day became the first product approved by the United States Food and Drug Administration for slowing myopia progression in children aged 8 to 12 at the start of treatment, followed by Chinese approval in August 2021 and Japanese approval in August 2025. Its two product categories are toric and multifocal lenses, which correct complex defects such as astigmatism and presbyopia as well as near and farsightedness, and spherical lenses, which cover simpler correction plus myopia management and other specialty lenses. Frequent replacement lenses are sold under Biofinity, the segment's highest grossing product, covering monthly silicone hydrogel spherical, toric, multifocal and toric multifocal lenses, and under Avaira Vitality for two-week lenses; single-use lenses are sold under MyDay, the premium line, and clariti 1 day, the most affordable line. Major manufacturing and distribution sites are in Belgium, Costa Rica, Hungary, Puerto Rico, the United Kingdom and the United States.

The contact lens market

The market for spherical lenses is growing as value-added products arrive, including lenses for lens-related dryness, aspherical optics, more highly oxygen permeable silicone hydrogels and myopia management lenses for children. The company sees room for contact lenses to take share where penetration of the vision correction market is low, and treats myopia management as a promising new market, with MiSight the only lens approved by the three regulators named to slow progression and correct myopia in age-appropriate children, supported by education of eye care practitioners, patients and families. It competes against Johnson & Johnson Vision Care, Alcon and Bausch and Lomb along with smaller companies, and to a lesser extent against eyeglasses and other vision correction including surgery, by producing high, medium and low-volume lenses in a variety of materials and a wide range of lens parameters.

CooperSurgical

The segment sells more than 600 products and services across fertility and women's health, split by point of care between products used in medical offices, ambulatory surgery centres and hospitals, largely by obstetricians and gynaecologists, and fertility products and services used in clinics. Office and surgical products cover gynaecology and obstetrics, including labour and delivery and the screening, diagnosis and treatment of women's health conditions, cryostorage of newborn cord blood and cord tissue in the United States, Canada and Australia, and Paragard, a hormone-free copper intrauterine device sold only in the United States that prevents pregnancy for up to ten years. Fertility products cover the in vitro fertilisation process, egg and sperm donation, cryopreservation and genomic services including genetic testing, with media, micro-tools and lab equipment for clinics. Major manufacturing, cryostorage and distribution sites are in Costa Rica, the Netherlands, the United Kingdom and the United States.

That market and its competitors

The filing states that obstetrics and gynaecology offices and fertility clinics are expected to keep moving away from private practice ownership towards group practices, private equity and corporate ownership, giving buyers more influence over supply chains, group purchasing and product evaluation, with the company's broad portfolio positioned to benefit as customers standardise and consolidate vendors. In fertility the competitors are Vitrolife, Nexpring and Fairfax Cryobank, plus clinics offering their own services; Johnson & Johnson, Baxter, Medtronic and Hologic compete with its medical devices; stem cell storage competes mainly with ViaCord; and Paragard competes with hormonal intrauterine devices from Bayer and AbbVie, contraceptives from Organon and other birth control, with a non-hormonal device already approved but not yet marketed.

Competing generally, and people

The markets are highly competitive and turn on technological and scientific advances, product quality and availability, price, customer service and manufacturing processes, with competitors that may have greater financial resources, larger research budgets and sales forces and more manufacturing capacity. Approximately 500 people work in research and development. At 31 October 2025 the workforce numbered more than 15,000, with 52% in the Americas, 42% in Europe, the Middle East and Africa and 6% in Asia Pacific.

From The Cooper Companies' annual report on Form 10-K for the year ended 31 October 2025. The filing

Compare with another name What $10,000 in Cooper Companies became

Next results: expected around 3 Dec 2026, last year 4 Dec 2025. Earnings calendar

Latest results

Latest quarterQ3 FY2026ended 31 July 2026 · 10-Q filed 9 September 2026
Revenue
$1.1 billion
+0.6% on the year · -1.4% on the quarter
Q4 FY2024Q3 FY2026
Net income
$433 million
+340.3% on the year
Q4 FY2024Q3 FY2026
Diluted EPS
$2.24
+357.1% on the year
Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

Read the Q3 FY2026 results →the 10-Q on EDGAR ↗
Last full yearFY2025ended 31 October 2025 · 10-K filed 5 December 2025
Revenue
$4.1 billion
+5.1% on the year
FY2018FY2025
Net income
$375 million
-4.4% on the year
FY2018FY2025
Diluted EPS
$1.87
-4.6% on the year
FY2018FY2025

this yearthe year beforeHover a bar for its figure.

The years before, in wordsCooper Companies (COO) reported revenue of $4.1 billion for fiscal 2025, the year ended 31 October 2025, up 5.1% on the year before. Net income was $375 million and diluted earnings per share $1.87. Revenue was $3.9 billion in fiscal 2024, $3.6 billion in fiscal 2023, $3.3 billion in fiscal 2022 and $2.9 billion in fiscal 2021. Net income in the same years was $392 million, $294 million, $386 million and $2.9 billion. Over the twelve months to 31 July 2026, Cooper Companies reported revenue of $4.2 billion and net income of $570 million. Revenue grew 11.0% a year, compounded, over the five years to fiscal 2025. Cooper Companies had 190 million shares outstanding at the latest filed count. At 31 July 2026 it carried $2.5 billion of debt and $155 million of cash. At the close of 6 November 2026 the market cap of Cooper Companies was $11.9 billion, 21.3 times its earnings over the last twelve months.
Read the FY2025 results →the 10-K on EDGAR ↗

Ratios

From the filings

ROE6.8%
ROCE5.0%
Operating margin12.8%
Net margin13.5%
FCF margin16.0%
Interest cover6.1x
Debt to equity0.31x
Cash conversion1.81x
Share count, last 12 months-4.4%
Sales CAGR, 3 years7.3%
Profit CAGR, 3 years-1.0%
EPS, TTM$2.93

At the close of 6 November 2026

Price$62.37
Market cap$11.9 billion
Stock P/E21.3x
Price to book1.4x
EV / EBITDA15.4x
Dividend yieldn/a
Market cap / sales2.8x
52-week high$84.32
52-week low$53.27
Price, 1 year-9.6%
Price CAGR, 3 years-9.2%
Price CAGR, 5 years-10.1%

29 ready-made ratios, from FCF yield to net debt to EBITDA, wait on the Formulas page, each with what it tells you. Browse and add them →

Worked from the filed figures; hover a name for the formula.
Read moreThe priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on the total debt Cooper Companies, Inc. states in its own filing, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.
COOgreeksoup.ai
Daily prices to 6 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read moreData provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.

Quarterly results

Q4 FY2021 *Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue7597878308438488588779309279329431,0031,0189651,0021,0601,0651,0241,0821,066
Cost of revenue257269297291311300294320321308311340341304323368414329346354
Gross profit502518532552537558583610606624631663678660679692651695735712
Gross margin66%66%64%65%63%65%66%66%65%67%67%66%67%68%68%65%61%68%68%67%
R&D25.526.226.328.729.131.632.636.536.739.538.939.037.740.745.544.641.444.342.541.6
SG&A312319322343358331408375388381380381391388399422419390676401
Operating income12913113314110415096.3152136153162192198182185176140213-31.0222
Operating margin17%17%16%17%12%17%11%16%15%16%17%19%19%19%18%17%13%21%-3%21%
Interest expense5.06.610.817.122.826.126.126.826.329.928.928.527.026.024.225.424.422.420.921.5
Pre-tax income12212216411772.412265.6119106120130164169153144152117192-48.4202
Tax rate9%22%23%16%10%31%39%28%21%32%32%36%30%32%39%35%28%32%n/a-114%
Net income11095.312798.465.584.639.885.384.581.288.910511810487.798.384.6131-77.9433
Net margin15%12%15%12%8%10%5%9%9%9%9%10%12%11%9%9%8%13%-7%41%
Diluted EPS$0.53$0.48$0.64$0.49$0.33$0.42$0.20$0.43$0.42$0.41$0.44$0.52$0.58$0.52$0.44$0.49$0.43$0.66-$0.40$2.24
Operating cash flow17416613226413116712414217412311120826819196.2261248261183342
Capital expenditure65.057.143.446.694.983.073.690.914511874.189.014089.478.196.998.010286.468.7
Free cash flow11010988.421735.883.650.651.629.24.636.911812810118.116415015996.4273
Buybacks0.078.50.00.00.00.00.00.00.0n/an/a0.0n/a0.040.652.719792.515.5339
Dividends paidn/an/an/a0.0n/an/an/a0.0n/a0.00.00.00.00.00.00.00.0n/an/an/a
Shares outstanding197m197m197m197m197m198m198m198m198m199m199m199m200m200m200m199m196m195m195m190m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Income statement (profit and loss)

FY2008FY2009FY2010FY2011FY2012FY2013FY2014FY2015 †FY2016 †FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025TTM
Revenue1,0471,0801,1591,3311,4451,5881,7181,7971,9672,1392,5332,6532,4312,9223,3083,5933,8954,0924,237
Cost of revenue4374844825265215616267277947739008978969671,1691,2351,3001,4101,444
Gross profit6105966778059241,0271,0921,0701,1731,3661,6321,7571,5351,9562,1402,3582,5962,6822,793
Gross margin58.2%55.2%58.4%60.5%63.9%64.7%63.5%59.6%59.6%63.9%64.4%66.2%63.1%66.9%64.7%65.6%66.6%65.5%65.9%
Research and development35.533.335.343.651.758.866.369.665.469.284.886.793.392.7110137155172170
Selling, general and administrative4293924335135656116837137237999739969921,2111,3421,5011,5341,6281,887
Operating income127150190228283306306237324429403547312506508533706683544
Operating margin12.1%13.9%16.4%17.1%19.6%19.3%17.8%13.2%16.5%20.1%15.9%20.6%12.8%17.3%15.3%14.8%18.1%16.7%12.8%
Interest expense53.044.136.717.311.89.28.018.126.233.482.768.036.823.157.310511410089.2
Pre-tax income74.0115124193275312297215296394332477266492475413582566462
Income tax10.014.311.617.326.815.424.710.420.721.119210.728.1-2,45389.5119190192-108
Effective tax rate13.5%12.4%9.3%9.0%9.7%4.9%8.3%4.8%7.0%5.4%57.8%2.2%10.5%-499.1%18.8%28.7%32.6%33.8%-23.3%
Net income64.01011131752482962702042743731404672382,945386294392375570
Net margin6.1%9.3%9.7%13.2%17.2%18.7%15.7%11.3%13.9%17.4%5.5%17.6%9.8%100.8%11.7%8.2%10.1%9.2%13.5%
Diluted EPS$0.35$0.55$0.61$0.91$1.26$1.49$1.38$1.03$1.40$1.88$0.70$2.33$1.20$14.79$1.94$1.48$1.96$1.87$2.93
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
From each year's 10-K, linked; TTM is the last four quarters.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Revenue by region FY2009 to FY2025

FY2009FY2010FY2011FY2012FY2013FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
United States6387138008799731,0041,0621,1411,1871,1621,2121,1041,3391,6381,8121,9662,05450.2%
Europe6126476977278059281,1401,1451,1878468557909589871,0411,1561,25330.6%
Rest of Worldn/an/an/an/an/an/an/an/an/a52458753862568374077478519.2%
Rest of World, Other Eliminations & Corporate-170-201-166-161-190-215-405-320-234n/an/an/an/an/an/an/an/an/a
United StatesEuropeRest of World FY2018 to FY2025
1,360FY20101,778FY20132,286FY20162,653FY20193,308FY20224,092FY2025

$ million; hover a block for its figure and share; the figure over a bar is its parts, before the lines named below; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in. Rest of World, Other Eliminations & Corporate is the company's own eliminations and corporate items, which take the parts to revenue: shown as filed, with no share and no block in the chart.

Cash flow

FY2008FY2009FY2010FY2011FY2012FY2013FY2014FY2015 †FY2016 †FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025TTM
Operating cash flow96.52232683363154164553915105946697134877396926087097961,033
Capital expenditure12593.973.810499.8178238243153127194292310214242392421362355
Free cash flow-28.4129194233215238217148357466475421176524450215288434678
Free cash flow margin-2.7%12.0%16.7%17.5%14.9%15.0%12.6%8.2%18.2%21.8%18.8%15.9%7.2%17.9%13.6%6.0%7.4%10.6%16.0%
Cash from investing-129-98.6-107-162-238-190-1,346-288-419-381-1,518-351-364-450-1,831-449-765-373-362
Cash from financing31.2-123-162-173-68.4-162842-107-1.4-228844-351-95.5-3111,194-17439.2-426-641
Depreciation and amortisation82.292.694.098.1111125138191198188275281287309346368375377384
Share-based compensation13.612.09.613.921.528.536.532.929.937.243.235.137.643.854.262.175.170.565.8
Buybacksn/an/a0.00.071.216775.867.30.055.00.015647.824.878.50.00.0290644
Dividends paid2.72.72.72.82.92.92.92.92.92.92.93.03.03.03.03.00.00.0n/a
Dividend per sharen/an/an/an/a$0.01$0.01$0.01$0.01$0.01$0.01$0.01$0.01$0.01$0.01$0.01$0.01n/an/an/a
Diluted shares, weighted180m182m186m193m197m199m196m197m196m198m199m200m198m199m199m199m200m200m193m
Shares outstanding at period endn/an/an/an/an/an/an/an/an/an/an/an/a196m197m197m198m200m196m190m
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
Cash paid in the year, from the cash flow statement.
Read moreThe dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet

FY2008FY2009FY2010FY2011FY2012FY2013FY2014FY2015 †FY2016 †FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025TTM
Funded by
Shareholders' equity1,4171,5401,6671,9372,1932,4052,5702,6682,7003,1763,3083,6283,8256,9427,1747,5518,0838,2398,328
Non-controlling interestn/an/an/a0.020.419.018.66.40.10.10.20.20.20.20.20.20.20.20.2
Short-term borrowingsn/a7.1n/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Debtn/a7746113803743451,3821,3491,3341,1732,0231,8261,7931,4792,7632,5692,5842,5052,544
Operating lease liabilitiesn/an/an/an/an/an/an/an/an/an/an/an/a237232206216231240n/a
Finance lease liabilitiesn/an/an/an/an/an/an/an/an/an/an/an/an/a1.53.73.42.41.81.6
Other liabilitiesn/a2302473073553694884384425107828208839521,3451,3201,4151,4081,799
Total liabilities and equityn/a2,5522,5252,6252,9413,1374,4584,4614,4764,8596,1136,2746,7389,60611,49211,65912,31512,39512,673
Owned
Fixed assetsn/a6035946096407409379678789109761,1321,2821,3481,4141,6291,8602,080n/a
Goodwilln/a1,2571,2621,2771,3701,3882,2212,1972,1652,3552,3922,4292,4472,5743,6103,6243,8383,8533,876
Intangible assetsn/a1151141282151994544114415051,5211,4051,2891,2721,8851,7101,7911,5861,446
Cash and equivalents1.93.93.65.212.877.425.216.410188.877.789.011695.9138121108111155
Receivablesn/a171197215234230276283291317375435435515558610717829789
Inventoryn/a261228254320339381420418454469507570586629736803846912
Other assetsn/a1421261371491651641661832303022775983,2163,2593,2293,1983,0905,496
Total assetsn/a2,5522,5252,6252,9413,1374,4584,4614,4764,8596,1136,2746,7389,60611,49211,65912,31512,39512,673
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
At the fiscal year end; the TTM column is the latest quarter end.
Read moreBoth totals are the company's own. Other liabilities is the filed total less the rows above it: payables, deferred revenue, taxes, borrowings the rows above do not carry and the rest; other assets is the same on the other side. Investments add the current and non-current lines as filed. Debt is the company's own stated total where it files one, otherwise its long-term debt with the current maturities, never parts added together. A row is left blank in a year where the lines shown overlap and the remainder would fall below nil.

Compounded growth

10 years5 years3 yearsTTM
Sales growth, compounded8.6%11.0%7.3%4.7%
Profit growth, compounded6.3%9.5%-1.0%39.8%
Return on equity, average10.6%12.2%4.4%4.6%
Yearly growth, compounded; TTM is the last four quarters against the four before.
Read moreReturn on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Questions

When does Cooper Companies report its next earnings?

Cooper Companies is expected to report its next results around 3 Dec 2026, the same weekday a year after it reported the same quarter last year on 4 Dec 2025. No day set by the company is on record yet.

What was Cooper Companies' revenue in fiscal 2025?

Cooper Companies (COO) reported revenue of $4.1 billion for fiscal 2025, the year ended 31 October 2025, up 5.1% on the year before.

How much did Cooper Companies earn in fiscal 2025?

Net income was $375 million for fiscal 2025, and diluted earnings per share $1.87.

What is Cooper Companies' P/E ratio?

At the close of 6 November 2026, Cooper Companies traded at 21.3 times its earnings over the twelve months to 31 July 2026.

What is Cooper Companies' market cap?

The market cap of Cooper Companies was $11.9 billion at the close of 6 November 2026.

How much debt does Cooper Companies have?

At 31 July 2026 Cooper Companies carried $2.5 billion of debt and $155 million of cash.

Peers: Medical Equipment

CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Smith & Nephew plc SNN *$13.7 billion21.7611.8%12.9%6.1%0.592.4%
Baxter International Inc. BAX$13.3 billionn/a-11.1%-1.9%5.3%1.322.0%
Glaukos Corp. GKOS$13.3 billionn/a-23.7%-25.5%46.9%0.00n/a
Penumbra Inc. PEN$12.6 billion80.459.9%12.1%17.0%0.00n/a
Cooper Companies, Inc. COO$11.9 billion21.296.8%12.8%4.7%0.31n/a
Align Technology Inc. ALGN$11.7 billion24.1711.4%14.9%4.4%0.00n/a
Insulet Corp. PODD$10.2 billion23.8727.2%18.4%26.5%0.61n/a
Bausch & Lomb Corp. BLCO$7.1 billionn/a-1.7%7.1%8.9%0.79n/a
Warby Parker Inc. WRBY$3.2 billion424.581.9%0.2%9.9%0.00n/a
National Vision Holdings, Inc. EYE$1.4 billion29.335.6%4.1%7.8%0.26n/a
Staar Surgical Co. STAA$1.3 billion1,815,851,369,755,783,936.000.1%0.2%42.4%0.00n/a
RxSight, Inc. RXST$190 millionn/a-20.9%-50.4%-14.3%0.00n/a
All 110 in Medical Equipment
CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Intuitive Surgical Inc. ISRG$156.9 billion54.7518.5%28.4%20.5%0.00n/a
Medtronic plc MDT$130.3 billion25.0710.4%18.1%9.8%0.562.8%
Stryker Corp. SYK$124.0 billion34.7015.4%20.7%7.9%0.641.1%
3M Co. MMM$95.7 billion27.6185.7%18.8%1.7%3.631.7%
Boston Scientific Corp. BSX$62.0 billion18.1113.7%18.7%8.9%0.47n/a
Edwards Lifesciences Corp. EW$58.8 billion57.679.4%21.6%13.4%0.06n/a
Becton Dickinson & Co. BDX$57.7 billion63.803.9%9.6%-2.6%0.692.0%
Medline Inc. MDLN$52.2 billion57.614.9%5.7%n/a1.07n/a
GE HealthCare Technologies Inc. GEHC$37.2 billion17.3818.5%13.3%6.9%0.860.2%
Resmed Inc. RMD$33.1 billion21.4226.8%33.0%9.0%0.071.0%
Dexcom Inc. DXCM$29.6 billion31.1439.1%24.0%13.0%0.49n/a
Koninklijke Philips N.V. PHG *$29.2 billion29.228.2%8.0%-1.0%0.741.3%
West Pharmaceutical Services Inc. WST$27.9 billion44.8721.5%23.0%12.6%0.070.2%
Steris plc STE$24.5 billion29.9311.4%19.0%8.1%0.261.0%
Zimmer Biomet Holdings, Inc. ZBH$20.0 billion26.736.0%13.6%7.0%0.590.9%
Solventum Corp. SOLV$15.4 billion101.513.2%5.6%-2.8%1.05n/a
Smith & Nephew plc SNN *$13.7 billion21.7611.8%12.9%6.1%0.592.4%
Baxter International Inc. BAX$13.3 billionn/a-11.1%-1.9%5.3%1.322.0%
Glaukos Corp. GKOS$13.3 billionn/a-23.7%-25.5%46.9%0.00n/a
Penumbra Inc. PEN$12.6 billion80.459.9%12.1%17.0%0.00n/a
Cooper Companies, Inc. COO$11.9 billion21.296.8%12.8%4.7%0.31n/a
Align Technology Inc. ALGN$11.7 billion24.1711.4%14.9%4.4%0.00n/a
Insulet Corp. PODD$10.2 billion23.8727.2%18.4%26.5%0.61n/a
Globus Medical Inc. GMED$9.5 billion17.4511.6%21.6%13.4%0.00n/a
Bausch & Lomb Corp. BLCO$7.1 billionn/a-1.7%7.1%8.9%0.79n/a
MSA Safety Inc. MSA$6.6 billion21.8621.1%20.2%8.1%0.781.3%
Teleflex Inc. TFX$6.0 billion18.338.7%9.4%20.9%0.460.9%
Haemonetics Corp. HAE$5.5 billion53.8311.6%12.8%4.1%1.26n/a
Merit Medical Systems Inc. MMSI$5.2 billion32.809.2%13.5%9.1%0.42n/a
LivaNova plc LIVN$5.0 billion30.0114.3%10.7%11.7%0.22n/a
MiniMed Group, Inc. MMED$4.7 billionn/an/an/an/a0.00n/a
Heartflow, Inc. HTFL$4.5 billionn/a-42.3%-37.8%n/a0.00n/a
Integer Holdings Corp. ITGR$4.3 billion42.486.0%8.2%-0.3%0.71n/a
ICU Medical Inc. ICUI$4.3 billion71.992.8%5.1%-5.9%0.53n/a
Envista Holdings Corp. NVST$4.0 billion6.5120.5%25.4%9.8%0.46n/a
Pulse Biosciences, Inc. PLSE$3.9 billionn/a-45.6%-5,821.1%1,637.2%0.00n/a
Warby Parker Inc. WRBY$3.2 billion424.581.9%0.2%9.9%0.00n/a
TransMedics Group, Inc. TMDX$3.1 billion23.8926.2%11.9%28.5%0.930.0%
iRhythm Holdings, Inc. IRTC$3.0 billionn/a-21.8%-5.7%21.6%3.68n/a
Axogen, Inc. AXGN$3.0 billionn/a-6.4%-5.2%24.3%0.00n/a
AtriCure, Inc. ATRC$3.0 billion195.032.8%2.9%13.8%0.11n/a
UFP Technologies Inc. UFPT$2.3 billion30.9015.8%15.5%8.6%0.20n/a
Establishment Labs Holdings Inc. ESTA$2.0 billionn/a-246.6%-6.6%38.3%17.17n/a
Dentsply Sirona Inc. XRAY$1.9 billionn/a-8.9%-1.5%-1.4%1.626.8%
Lemaitre Vascular Inc. LMAT$1.9 billion29.4214.7%27.7%11.8%0.391.2%
Inspire Medical Systems, Inc. INSP$1.8 billion18.5712.2%1.8%-0.2%0.00n/a
Kestra Medical Technologies, Ltd. KMTS$1.7 billionn/a-67.4%-134.5%60.7%0.33n/a
Butterfly Network, Inc. BFLY$1.7 billionn/a-29.1%-46.9%39.3%0.000.0%
Enovis Corp. ENOV$1.6 billionn/a-35.3%-20.6%3.3%0.84n/a
NovoCure Ltd. NVCR$1.6 billionn/a-34.7%-17.2%12.9%0.56n/a
Conmed Corp. CNMD$1.5 billion21.306.9%9.9%1.6%0.771.2%
National Vision Holdings, Inc. EYE$1.4 billion29.335.6%4.1%7.8%0.26n/a
Cadre Holdings, Inc. CDRE$1.4 billion34.4211.2%10.7%18.3%1.011.2%
Staar Surgical Co. STAA$1.3 billion1,815,851,369,755,783,936.000.1%0.2%42.4%0.00n/a
Procept BioRobotics Corp. PRCT$1.2 billionn/a-34.9%-33.6%17.5%0.16n/a
Tandem Diabetes Care Inc. TNDM$1.2 billionn/a-36.4%-2.4%6.8%4.47n/a
Alphatec Holdings, Inc. ATEC$1.2 billionn/an/a-3.6%15.3%n/an/a
Iradimed Corp. IRMD$1.1 billion46.1422.5%32.3%11.0%0.000.9%
Si-Bone, Inc. SIBN$1.1 billionn/a-7.4%-7.6%14.0%0.190.0%
Integra LifeSciences Holdings Corp. IART$1.0 billion78.971.2%4.4%0.8%1.71n/a
Ceribell, Inc. CBLL$1.0 billionn/a-62.9%-69.8%31.3%0.17n/a
Artivion, Inc. AORT$986 millionn/a-3.9%2.3%14.0%0.81n/a
Bioventus Inc. BVS$893 million13.2523.8%9.7%3.9%0.96n/a
Beta Bionics, Inc. BBNX$855 millionn/a-20.7%-72.7%43.7%0.00n/a
Orthopediatrics Corp. KIDS$828 millionn/a-10.0%-9.4%16.1%0.31n/a
Tactile Systems Technology Inc. TCMD$585 million25.2610.5%9.4%14.4%0.00n/a
Sight Sciences, Inc. SGHT$558 millionn/a-57.8%-29.5%16.2%0.83n/a
Anteris Technologies Global Corp. AVR$553 millionn/a-41.2%-4,738.4%-9.6%0.00n/a
Delcath Systems, Inc. DCTH$517 million1,494.000.4%-1.9%35.8%0.00n/a
Avita Medical, Inc. RCEL$513 millionn/an/a-33.9%17.0%n/an/a
Angiodynamics Inc. ANGO$497 millionn/a-20.1%-11.2%8.2%0.00n/a
Mimedx Group, Inc. MDXG$482 millionn/a-9.1%-8.3%-22.8%0.00n/a
SS Innovations International, Inc. SSII$430 millionn/a-23.3%-15.8%89.7%0.00n/a
NeuroPace Inc. NPCE$428 millionn/a-160.9%-15.3%11.6%4.970.0%
Shoulder Innovations, Inc. SI$426 millionn/a-28.2%-54.4%n/a0.13n/a
Cerus Corp. CERS$407 millionn/a-9.7%-1.0%n/a0.84n/a
Carlsmed, Inc. CARL$395 millionn/a-43.1%-61.1%n/a0.18n/a
Mobia Medical, Inc. MOBI$372 millionn/an/an/an/a0.05n/a
Embecta Corp. EMBC$350 million4.18n/a21.9%-7.6%n/a7.4%
Orchestra BioMed Holdings, Inc. OBIO$341 millionn/a-305.5%-181.4%986.1%1.80n/a
Orthofix Medical Inc. OFIX$320 millionn/a-14.4%-4.7%3.0%0.52n/a
CapsoVision, Inc. CV$316 millionn/a-226.6%-217.1%n/a0.00n/a
Cytosorbents Corp. CTSO$308 millionn/an/a-34.7%3.1%n/an/a
Sanara MedTech Inc. SMTI$291 millionn/a-403.0%n/a12.9%5.85n/a
ClearPoint Neuro, Inc. CLPT$276 millionn/a-132.5%-70.6%32.5%1.86n/a
InfuSystem Holdings, Inc. INFU$272 million33.3414.4%9.3%2.5%0.35n/a
Treace Medical Concepts, Inc. TMCI$265 millionn/a-90.5%-24.4%-7.1%0.91n/a
Profound Medical Corp. PROF$264 millionn/a-76.4%-145.1%65.3%0.11n/a
Orasure Technologies Inc. OSUR$238 millionn/a-15.5%-48.1%-18.9%0.00n/a
Utah Medical Products Inc. UTMD$231 million22.138.6%28.4%-7.0%0.00n/a
Electromed, Inc. ELMD$226 million20.5820.9%18.8%15.3%0.00n/a
PRO DEX Inc. PDEX$202 million17.3524.4%16.8%13.3%0.33n/a
TriSalus Life Sciences, Inc. TLSI$200 millionn/a-430.7%-67.7%25.2%5.05n/a
Anika Therapeutics, Inc. ANIK$195 millionn/a-1.3%-2.1%9.4%0.00n/a
RxSight, Inc. RXST$190 millionn/a-20.9%-50.4%-14.3%0.00n/a
Inogen Inc. INGN$161 millionn/a-14.1%-8.7%3.2%0.00n/a
Edap TMS SA FOCL$158 millionn/a-104.3%-35.4%n/a0.99n/a
Koru Medical Systems, Inc. KRMD$143 millionn/a-10.1%-3.7%22.4%0.00n/a
Apyx Medical Corp. APYX$124 millionn/a-87.6%-5.5%24.4%3.89n/a
Pulmonx Corp. LUNG$112 millionn/a-124.4%-44.4%-3.2%1.11n/a
Stereotaxis, Inc. STXS$111 millionn/a-182.3%-75.7%-5.5%0.00n/a
SkinHealth Systems Inc. SKIN$102 millionn/a-32.8%2.4%-4.4%4.36n/a
Lakeland Industries Inc. LAKE$88 millionn/a-21.4%-4.1%-0.4%0.23n/a
Outset Medical, Inc. OM$79 millionn/a-85.4%-51.2%1.6%1.18n/a
Neuraxis, Inc. NRXS$77 millionn/a-114.0%-144.5%65.2%0.01n/a
Lucid Diagnostics Inc. LUCD$76 millionn/a-478.3%-930.8%24.9%2.15n/a
Lensar, Inc. LNSR$66 millionn/a232.8%-13.5%3.3%0.25n/a
NutriBand Inc. NTRB$66 millionn/a-130.7%-435.6%-37.3%0.00n/a
RenovoRx, Inc. RNXT$55 millionn/a-140.2%-489.0%n/a0.00n/a
PAVmed Inc. PAVM$10 millionn/a-34.5%-23,841.1%-89.0%0.43n/a
5 companies share its SEC industry code (Ophthalmic Goods); the rest are the names nearest in size in its wider industry, Medical Equipment, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read moreBy market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.

The public record on COO

Dividends$0.0075 a share in FY2023
Filings17 in twelve months: 10 current reports (8-K), about 5 officer or director change; 4 results of operations; 3 regulation FD disclosure; 2 other events; 2 material agreement
Planned insider salesno Form 144 notice in twelve months
Options tapeput/call 0.26 by open interest at the 6 November 2026 close; the straddle prices a 6.3% move to 20 November 2026
13F holders677 funds reported a position for the quarter to 30 June 2026; largest BlackRock, Inc.
Insider trading0 sales and 10 purchases on Form 4 in twelve months
Congress2 House trades disclosed in six months
Short interest9.1 million shares short, 2.42 days to cover at 15 October 2026
Documentsthe 10-K, the 10-Qs, the proxy and 4 earnings press releases, each linked

Filings

FilingPeriodFiledWhere
10-Q31 July 20269 September 2026EDGAR
10-Q30 April 20265 June 2026EDGAR
10-Q31 January 20266 March 2026EDGAR
10-K31 October 20255 December 2025EDGAR
10-Q31 July 202528 August 2025EDGAR
10-Q30 April 202530 May 2025EDGAR
10-Q31 January 20257 March 2025EDGAR
10-K31 October 20246 December 2024EDGAR
10-Q31 July 202429 August 2024EDGAR
10-Q30 April 202431 May 2024EDGAR

Reading about a stock somewhere else? Our free Chrome extension, GreekSoup Stock Ticker Lookup: Earnings, Insider Trades, 13F Holders, shows the latest quarter against a year ago, insider trades and 13F holders when you hover a $ticker such as $AAPL.